Fatty liver

Revision as of 02:37, 9 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
Jump to navigation Jump to search

For patient information click here

Fatty liver
ICD-10 K70, K76.0
ICD-9 571.0, 571.8
DiseasesDB 18844
eMedicine med/775 
MeSH C06.552.241

Template:Search infobox

Editor-In-Chief: Yohanes Buang, PhD [1]

Overview

Fatty liver (also known as steatorrhoeic hepatosis or steatosis hepatis) is the fatty degeneration of the parenchymal cells causing a yellow discoloration of the liver. It is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis. Despite having multiple causes, fatty liver disease (FLD) can be considered a single disease that occurs worldwide in those with excessive alcohol intake and those who are obese (with or without effects of insulin resistance). The condition is also associated with other diseases that influence fat metabolism[1]. Morphologically it is difficult to distinguish alcoholic FLD from non alcoholic FLD and both show micro-vesicular and macrovesicular fatty changes at different stages.

Causes

Different stages of liver damage

Fatty liver is commonly associated with alcohol or metabolic syndrome (diabetes, hypertension and dyslipidemia) but can also be due to any one of many causes[2][3]:

Metabolic
Abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolmans disease, acute fatty liver of pregnancy, lipodystrophy
Nutritional
Malnutrition, total parenteral nutrition, severe weight loss, refeeding syndrome, jejuno-ileal bypass, gastric bypass, jejunal diverticulosis with bacterial overgrowth
Drugs and toxins
Amiodarone, methotrexate, diltiazem, highly active antiretroviral therapy, glucocorticoids, tamoxifen, environmental hepatotoxins (e.g. phosphorus, toxic mushroom)
Other
Inflammatory bowel disease, HIV

Pathology

Fatty change represents the intra-cytoplasmic accumulation of triglyceride (neutral fats). At the beginning, the hepatocytes present small fat vacuoles (liposomes) around the nucleus - microvesicular fatty change. In this stage liver cells are filled with multiple fat droplets that do not displace centrally located nucleus. In the late stages, the size of the vacuoles increases pushing the nucleus to the periphery of the cell giving characteristic signet ring appearance - macrovesicular fatty change. These vesicles are well delineated and optically "empty" because fats dissolve during tissue processing. Large vacuoles may coalesce, producing fatty cysts - which are irreversible lesions. [2]. Macrovesicular steatosis is the most common form and is typically associated with alcohol, diabetes, obesity and corticosteroids. Acute fatty liver of pregnancy and Reye's syndrome are examples of severe liver disease caused by microvesicular fatty change[4]. The diagnosis of steatosis is made when fat in the liver exceeds 5–10% by weight[5][6][1].

Mechanism leading to hepatic steatosis

Defects in fat metabolism is responsible for pathogenesis of FLD which may be due to imbalance in energy consumption and its combustion resulting in lipid storage or can be a consequence of peripheral resistance to insulin, whereby the transport of fatty acids from adipose tissue to the liver is increased[7][1]. Impairment or inhibition of receptor molecules (PPAR-α, PPAR-γ and SREBP1) that control the enzymes responsible for the oxidation and synthesis of fatty acids appears to contribute towards fat accumulation. In addition alcoholism is known to damage mitochondria and other cellular structure further impairing cellular energy mechanism. On the other hand non alcoholic FLD may begin as excess of unmetabolised energy in liver cells. Hepatic steatosis is considered reversible and to some extent nonprogressive if there is cessation or removal of underlying cause.

Severe fatty liver is accompanied by inflammation, a situation that is referred to as steatohepatitis. Progression to alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH) depend on persistence or severity of inciting cause. Pathological lesions in both conditions are similar. However, the extent of inflammatory response varies widely and does not always correlate with degree of fat accumulation. Steatosis (retention of lipid) and onset of steatohepatitis may represent successive stages in FLD progression[8].

Liver with extensive inflammation and high degree of steatosis often progresses to more severe forms of the disease[9]. Hepatocyte ballooning and hepatocyte necrosis of varying degree are often present at this stage. Liver cell death and inflammatory responses lead to the activation of stellate cells which play a pivotal role in hepatic fibrosis. The extent of fibrosis varies widely. Perisinusoidal fibrosis is most common, especially in adults, and predominates in zone 3 around the terminal hepatic veins[10].

The progression to cirrhosis may be influenced by the amount of fat and degree of steatohepatitis and by a variety of other sensitizing factors. In alcoholic FLD the transition to cirrhosis related to continued alcohol consumption is well documented but the process involved in non-alcoholic FLD is less clear.

Diagnosis

Most individuals are asymptomatic and are usually discovered incidentally because of abnormal liver function tests or hepatomegaly noted in unrelated medical condition. Elevated liver biochemistry is found in 50% of patients with simple steatosis[11]. The serum ALT level usually is greater than the AST level in non-alcoholic variant and the opposite in alcoholic FLD.

Imaging studies are often obtained during evaluation process. Ultrasonography reveals a "bright" liver with increased echogenicity. A fatty liver has lower density than spleen on CT scan and fat appears bright in T1 weighted MRI. No radiological modality is however able to distinguish simple steatosis from advanced NASH. Histological diagnosis by liver biopsy is sought when assessment of severity is indicated.

CT

Findings are

  • A decrease in mean hepatic attenuation values proportional to the degree of increase of the hepatic triglycerids.
  • Intrahepatic vessels are more clearly distinguished as hyperattenuating structures from the surrounding liver parenchyma
  • In normal individuals the attenuation value of the liver is slightly higher than that of the spleen. In fatty liver infiltration the attenuation values of both organs tend to be equal or the ratios may be reversed.
  • Does not cause any mass effect nor contour deformation of the organ.
  • Intrahepatic vessels follow their normal course through the lesion without deformity.

Patient #1

Patient #2: Perivascular fatty infiltration

Patient #3: Fatty infiltration on ultrasound

Patient #4: Fatty liver on ultrasound. Note that liver is very echogenic when compared to right kidney

Differential Diagnosis

Flow chart for diagnosis, modified from[3]
 
 
 
Elevated liver enzyme
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serology to exclude viral hepatitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging study showing
fatty infiltrate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess alcohol intake
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Less than 2 drinks per day‡
 
More than 2 drinks per day‡
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non alcoholic fatty liver disease likely
 
Alcoholic fatty liver disease likely
 
 
Criteria for nonalcoholic fatty liver disease:
consumption of ethanol less than 20g/day for woman and 30g/day for man[12]

Treatment and prevention

The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage.

Complication

Up to 10% of cirrhotic alcoholic FLD will develop hepatocellular carcinoma. Overall incidence of liver cancer in non-alcoholic FLD has not been assessed yet but the association is well established[14].

Epidemiology

FLD is prevalent among 10%- 24% of general population in various countries[2]. However among obese individuals the condition is observed in up to 75% of people, 35% of whom, despite no evidence of excessive alcohol consumption, will lead to non alcoholic FLD[15]. It is the commonest cause of abnormal liver function test in the US[2]. African Americans and Mexican Americans have higher frequencies of unexplained serum aminotransferase elevations than those reported in whites but prevalence of FLD among different racial groups is not known.

See also

Reference

  1. 1.0 1.1 1.2 Reddy JK, Rao MS (2006). "Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation". Am. J. Physiol. Fatty liver disease is one of the most deadly dieases ever to be found in someone who has and its very contasious so if someons has if i were u i wouldnt be hanging around with them well thats all from me see u next time. ËĒȲȳǖGastrointest. Liver Physiol. 290 (5): G852–8. doi:10.1152/ajpgi.00521.2005. PMID 16603729.
  2. 2.0 2.1 2.2 Angulo P (2002). "Nonalcoholic fatty liver disease". N. Engl. J. Med. 346 (16): 1221–31. doi:10.1056/NEJMra011775. PMID 11961152.
  3. 3.0 3.1 Bayard M, Holt J, Boroughs E (2006). "Nonalcoholic fatty liver disease". American family physician. 73 (11): 1961–8. PMID 16770927.
  4. Goldman, Lee (2003). Cecil Textbook of Medicine -- 2-Volume Set, Text with Continually Updated Online Reference. Philadelphia: W.B. Saunders Company. ISBN 0721645631.
  5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P (2005). "The natural history of nonalcoholic fatty liver disease: a population-based cohort study". Gastroenterology. 129 (1): 113–21. PMID 16012941.
  6. Crabb DW, Galli A, Fischer M, You M (2004). "Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha". Alcohol. 34 (1): 35–8. doi:10.1016/j.alcohol.2004.07.005. PMID 15670663.
  7. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R (2004). "Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis". Diabetes Care. 27 (8): 2057–66. PMID 15277442.
  8. Day CP, James OF (1998). "Steatohepatitis: a tale of two "hits"?". Gastroenterology. 114 (4): 842–5. PMID 9547102.
  9. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM (2004). "Pathologic features associated with fibrosis in nonalcoholic fatty liver disease". Hum. Pathol. 35 (2): 196–9. PMID 14991537.
  10. Zafrani ES (2004). "Non-alcoholic fatty liver disease: an emerging pathological spectrum". Virchows Arch. 444 (1): 3–12. doi:10.1007/s00428-003-0943-7. PMID 14685853.
  11. Sleisenger, Marvin (2006). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders Company. ISBN 1416002456.
  12. Adams LA, Angulo P, Lindor KD (2005). "Nonalcoholic fatty liver disease". CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 172 (7): 899–905. doi:10.1503/cmaj.045232. PMID 15795412.
  13. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:142 isbn=1591032016
  14. Qian Y, Fan JG (2005). "Obesity, fatty liver and liver cancer". HBPD INT. 4 (2): 173–7. PMID 15908310.
  15. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K (2005). "The metabolic syndrome as a predictor of nonalcoholic fatty liver disease". Ann. Intern. Med. 143 (10): 722–8. PMID 16287793.

External links


Template:Gastroenterology

de:Fettleber it:Steatosi epatica fi:Rasvamaksa

Template:WikiDoc Sources